

# Agnieszka Czarniecka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7779135/publications.pdf>

Version: 2024-02-01

30  
papers

2,847  
citations

361045

20  
h-index

454577

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3180  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	3.8	775
2	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	0.8	448
3	External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope, 2013, 123, S1-14.	1.1	263
4	Gene Expression Profile of Papillary Thyroid Cancer: Sources of Variability and Diagnostic Implications. Cancer Research, 2005, 65, 1587-1597.	0.4	238
5	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
6	Heterogeneity of Thyroid Cancer. Pathobiology, 2018, 85, 117-129.	1.9	117
7	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Molecular and Cellular Endocrinology, 2010, 322, 8-28.	1.6	114
8	Patient Age-Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	0.8	102
9	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	1.8	80
10	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	3.0	60
11	BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surgery, 2016, 5, 495-505.	0.5	58
12	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58
13	BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. PLoS ONE, 2015, 10, e0143688.	1.1	49
14	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	1.3	41
15	Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients. International Journal of Molecular Sciences, 2018, 19, 2647.	1.8	37
16	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
17	Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?. International Journal of Molecular Sciences, 2017, 18, 1817.	1.8	34
18	Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours. International Journal of Molecular Sciences, 2017, 18, 1184.	1.8	32

#	ARTICLE	IF	CITATIONS
19	The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS ONE, 2015, 10, e0132821.	1.1	31
20	Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. BMC Medical Genomics, 2013, 6, 38.	0.7	28
21	Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level. Thyroid Research, 2013, 6, S9.	0.7	14
22	TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. Cancers, 2020, 12, 1597.	1.7	13
23	Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. Endokrynologia Polska, 2010, 61, 462-6.	0.3	10
24	Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision. Thyroid Research, 2010, 3, 8.	0.7	9
25	Impact of the Tumor Microenvironment on the Gene Expression Profile in Papillary Thyroid Cancer. Pathobiology, 2020, 87, 143-154.	1.9	8
26	Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma – Do They Exist?. International Journal of Molecular Sciences, 2020, 21, 4629.	1.8	5
27	Unsupervised analysis of follicular thyroid tumours transcriptome by oligonucleotide microarray gene expression profiling. Endokrynologia Polska, 2013, 64, 328-334.	0.3	3
28	Definitive treatment of Graves’ disease in children and adolescents. Endokrynologia Polska, 2021, 72, 661-665.	0.3	2
29	Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015. Frontiers in Endocrinology, 2021, 12, 718833.	1.5	1
30	European perspective on active surveillance for papillary thyroid microcarcinoma – are we ready?. Annals of Thyroid, 0, 5, 15-15.	1.0	1